Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.

Psychiatry ResJun 10, 2026 (epub)
Clinical ResearchPsychiatry

Rune Andreas Kroken, Erik Johnsen, Renata Alisauskiene et al.

✦ AI-curated · Sources linked

In 30 seconds

This pragmatic randomized controlled trial evaluated the immunomodulatory effects of amisulpride, aripiprazole, and olanzapine in 144 patients with schizophrenia-spectrum disorders. Results indicated that amisulpride significantly reduced pro-inflammatory IL-1β levels compared to aripiprazole and olanzapine, with a combined pro-inflammatory variable decreasing by 0.52 standard deviations after 12 months of treatment.

Key findings

  • Amisulpride treatment led to a significant reduction in pro-inflammatory IL-1β levels over 12 months.
  • Amisulpride showed greater anti-inflammatory effects on IL-10 compared to aripiprazole.
  • Aripiprazole reduced IL-12p70 more than amisulpride.
  • The combined pro-inflammatory variable decreased by 0.52 standard deviations after amisulpride treatment.

Why it matters

Understanding the differential immunomodulatory effects of antipsychotics can inform treatment choices in schizophrenia, potentially improving patient outcomes by targeting inflammation.

Source

PubMed · PMID 42322923

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.